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Chuanyi Ning1,2,3,4, Kumi M. Smith5, Chase D. McCann6, Fengyu Hu1, Yun Lan1, 
Fuchun Zhang1, Hao Liang4, Jinmin Zhao4, Joseph D. Tucker2,3 & Weiping Cai1,2
The primary objective of this study was to obtain insights into the outcomes of people living with 
HIV who accessed services through HIV/AIDS sentinel hospital-based and ART service delivery in 
China. Post-hoc analyses of an open cohort from an observational database of 22 qualified HIV/AIDS 
sentinel hospital-based and two CDC-based drug delivery facilities (DDFs) in Guangdong Province was 
completed. Linkage to care, mortality and survival rates were calculated according to WHO criteria. 
12,966 individuals received ART from HIV/AIDS sentinel hospitals and 1,919 from DDFs, with linkage 
to care rates of 80.7% and 79.9%, respectively (P > 0.05). Retention rates were 94.1% and 84.0% in 
sentinel hospitals and DDFs, respectively (P < 0.01). Excess mortality was 1.4 deaths/100 person-
years (95% CI: 1.1, 1.8) in DDFs compared to 0.4 deaths/100 person-years (95% CI: 0.3, 0.5) in hospitals 
(P < 0.01). A Cox-regression analysis revealed that mortality was much higher in patients receiving 
ART from the DDFs than sentinel hospitals, with an adjusted HR of 3.3 (95% CI: 2.3, 4.6). A crude HR of 
treatment termination in DDFs was 7.5 fold higher (95% CI: 6.3, 9.0) compared to sentinel hospitals. 
HIV/AIDS sentinel hospital had better retention, and substantially lower mortality compared to DDFs.
Over the past two decades the number of people receiving antiretroviral therapy (ART) on the global scale has 
been steadily increasing by a large margin each year1,2. With the continuous growth in the number of people living 
with HIV/AIDS, the tasks of treating and managing follow-up visits becomes increasingly difficult. This is espe-
cially true for low and middle-income countries (LMIC) where HIV prevalence is often higher and the number 
of adequately trained medical personnel is limited. Additionally, people living in LMIC face multiple structural 
challenges to medication adherence including lack of transportation, as well as the social organizations involved 
in response. The promise of HIV treatment as prevention has focused attention on how to best implement treat-
ment practices with many cluster-randomized trials investigating competing strategies (HPTN 078, 071, 065)3–5. 
Despite these initial suggestions of success, the barriers to implementation of test-and-treat strategies need to be 
more fully evaluated.
Numerous countries around the world have formulated and improved relevant policies concerning publicity, 
education, comprehensive intervention, and follow-up visit management for HIV treatment6–8. In sub-Saharan 
Africa, increased funding made available through the Global Fund to Fight AIDS, Tuberculosis and Malaria and 
the President’s Emergency Plan for AIDS Relief (PEPFAR) has helped focus intervention strategies on patients’ 
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day-to-day adherence to ART9,10. In the United States, a recent study revealed that 72.8% of HIV-infected patients 
received care at facilities supported by the Ryan White HIV/AIDS Program11. Although many countries have 
significantly improved access to ART programs, achieving and maintaining a satisfactory long-term retention rate 
remains probelmatic12. It has been suggested that programs such as these, combined with adequate health facility 
infrastructure, can help serve patients with multiple social determinants of poor health and have been associated 
with improved outcomes13.
The process of ART delivery in China, however, is very region specific, owing to its size and epidemiological 
heterogeneity as well as the imbalance of economic autonomy14,15. Since beginning a pilot combination antiret-
roviral therapy (cART) program among former plasma donors in 2002, China has rapidly scaled up the National 
Free Antiretroviral Treatment Program (NFATP) in Center for Disease Control (CDC)-based ART service 
delivery facilities16. Chinese health authorities are expanding treatment-based prevention strategies, partially 
based on evidence that ART is already slowing the incidence of HIV infections in China17–19. In China, 90% of 
HIV-infected patients receiving ART treatment were linked to at least one free testing of viral load, and more than 
50% of patients had already accessed free medicine through ART service delivery facilities20. By the end of 2014, 
more than 295,358 patients across the country had received free antiretroviral treatment20. However, implementa-
tion of this treatment model was driven by thousands of CDC-based ART service delivery facilities focused solely 
on drug delivery, where delegation of physician tasks to less well-trained staff has hampered the effectiveness of 
antiretroviral therapy. In contrast, Guangdong Province has established a system of Sentinel hospitals in which 
patients wishing to receive HIV treatment through the NFATP are cared for by highly trained Infectious Disease 
specialists.
As the Chinese government has emphasized the importance of comprehensive HIV treatment and 
treatment-as-prevention strategies, health systems research on decentralizing HIV services is essential to achiev-
ing this goal21. Therefore, it is important to assess if variations in drug delivery models impact relative effective-
ness of treatment-as-prevention based strategies. Here we examine two ART delivery models currently used 
within the Guangdong Province of China to determine the extent to which such differences should be factored 
into policy. To evaluate patients’ outcome and retention rate of HIV/AIDS Highly Active ART (HAART) program 
on HIV-infected patients in the sentinel hospital and drug delivery facilities (DDFs), we analyzed data on mortal-
ity, immunologic response status, and risk factors of all previously treatment naive adult patients enrolled in the 
China NFATP of Guangdong province between 2005–2014.
Methods
Study Design and Setting. Data for this study were obtained through the NFATP observational database, 
described previously2. All patients with at least one visit to 24 health care facilities who initiated antiretrovi-
ral therapy from January 2005 through 30 June 2014 were included in this analysis. Patients were eligible for 
inclusion in this study if they had ever received ART through the NFATP and were 18 years of age or older at 
treatment initiation. At all sites, patients testing positive for HIV were provided with antiretroviral treatment 
counseling in the clinic. Patients were excluded if they did not start triple drug therapy, had missing treatment 
regimen information, or used ART outside of national guidelines. Patients who initiated treatment but failed to 
return for scheduled appointments were contacted and reason for termination was recorded. If, after multiple 
attempts, patients could not be contacted they were recorded as loss of follow-up. Treatment facility transfers and 
death were determined based upon linking patient unique Identity Number. The main outcomes evaluated were 
mortality and retention status, while risk factors associated with death were also evaluated in this study and were 
calculated according to World Health Organization (WHO) criteria.
Ethics Statement. The institutional review board of the Guangzhou Eighth People’s Hospital approved this 
analysis, according to the international and Chinese ethical guidelines. All the methods and the data analysis pro-
tocols were carried out in accordance with the WHO approved guidelines. Informed consent was obtained from 
all subjects prior to enrollment in this cohort.
Definition of HIV/AIDS sentinel hospitals and DDFs. Based on WHO guidelines and expert consensus 
on HIV/AIDS care in China, we defined AIDS sentinel hospitals according to the following criteria: (1) hospitals 
specific for infectious disease treatment or general hospitals with a department of infectious diseases, including 
traditional medicine hospitals, (2) the department of infectious diseases should have at least two physicians (at 
least one infectious disease fellow) and 3 nurses, all of whom were qualified by the Ministry of Health or Health 
Office of Clinical Study for the treatment of people living with HIV and (3) hospitals should have an HIV screen-
ing laboratory, HIV screening techniques, blood testing, liver function and kidney function testing equipment 
and technology, x-ray inspection equipment and techniques, opportunistic infections testing equipment and 
technology. Since 2005, 22 of the professional or general hospitals in Guangdong province qualified as HIV/AIDS 
sentinel hospitals, and two chronic disease centers which lead by the Center for Disease Control of Guangdong 
were defined as drug delivery facilities (DDFs). The latter served multiple functions of prevention, monitoring, 
and control of chronic and infectious diseases led by the CDC of Guangdong. The two different treatment facility 
models were all based on the NFATP guidelines described previously22,23. In Guangdong province, during ART in 
sentinel hospitals, CD4 cell count testing was completed every 6 months, and plasma viral load was quantified at 
least once per year at Guangzhou Eighth People’s Hospital. In addition, hepatic function was monitored at months 
0, 0.5, 1, 2, 3, 6 of cART, and every 6 months thereafter. Laboratory results were compared at baseline as well as at 
the last follow up visit for participants in sentinel hospitals and ART service delivery health facilities. Geographic 
location was taken into consideration as a possible factor of death and drug stoppage after initiation of ART.
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Statistical Analysis. Data collected included demographic characteristics, current symptoms, laboratory 
results, treatment regimen start and stop dates and the reason for treatment change or termination. We compared 
baseline characteristics between cohorts using the Mann-Whitney test for continuous variables, because none 
fulfilled the Kolmogorov-Smirnov test for normality. We used the Pearson chi-square statistic for dichotomous 
and categorical variables. We used Cox proportional hazards modeling to assess hazard ratio (HR) estimated 
potential risk factors. We entered covariates that we predetermined to be clinically significant into full multivari-
ate Cox models. We calculated survival curves by using life tables (SPSS, Chicago, Illinois) and assessed statistical 
significance between groups using the log-rank test because the assumption of proportionality was fulfilled. We 
used SPSS, version 19.0, SAS, version 9.2 (SAS Institute, Cary, NC), and ArcGIS version 10.2 (Esri, Redlands, CA) 
for all analyses. All hypothesis testing was 2-sided, with a level of 0.05 considered significant.
Results:
Demographic Characteristics. Of the 18,921 HIV patients seen at one of the 22 HIV/AIDS sentinel hos-
pitals or 2 ART delivery health facilities in Guangdong Province between January 2005 and June 2014, 16,757 
(88.6%) initiated cART. Of those, 1,872 were excluded from the analysis because of loss to follow up; 1,257 
because there was no follow up visit within the study dates, and 615 because the patient transferred to a different 
province to receive ART. Among the 14,885 patients included in this analysis, 12,966 (87.1%) received treatment 
at a sentinel hospital and 1,919 (12.9%) received treatment at a CDC DDF (Fig. 1).
Overall, the mean age of participants was 38.5 years, 73.2% were men, 55.6% were infected through hetero-
sexual transmission, 19.1% through injection drug use (IDU), 18.4% through male-to-male homosexual trans-
mission, and 29.2% had baseline symptoms within the last 3 months. Univariate analysis showed significance 
differences were observed between the two groups (P < 0.05) in WHO Clinical Stage of HIV/AIDS, CD4 cell 
count, prior treatment for Tuberculosis (TB) before ART, Hepatitis C Virus (HCV) co-infection or current use of 
Cotrimoxazole (Table 1). DDFs had a slightly higher percentage of females (28.1% vs 26.6%) and a significantly 
higher proportion of participants with HCV co-infection (26.8% vs 8.0%, P < 0.01 ) compared to sentinel hospi-
tals. The mean age of patients seen in sentinel hospitals (38.2 ± 11.7) was lower, although not significantly, than 
those seen at DDFs (41.0 ± 11.6), however mortality occurred at a significantly younger age in the DDFs than the 
sentinel hospitals (40.9 ± 10.8 vs 42.6 ± 13.2, P < 0.01; Table 2).
Figure 1. Flow chart index tests in patients included in sentinel hospital-based and CDC-based ART 
Service Delivery in the study. 
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During the last follow up visit, immunologic response improved greatly after initiating therapy, especially in 
patients receiving ART management in sentinel hospitals. For example, the interquartile range (IQR) of CD4 cell 
count at baseline was 172 (IQR, 57–261), and 369 (IQR, 250–497) at the last visit in sentinel hospital. This is in 
contrast to DDFs where baseline was 160 (IQR, 59–258), and increased to only 264 (IQR, 175–392) at the last 
visit (369 vs 264, P < 0.01). Although viral load was not significantly different between these two sites, manage-
ment of antiretroviral adverse effects, based upon usage of hemodlastase, glutamic-oxalacetic transaminase, and 
glutamic-pyruvic transaminase, was better at sentinel hospitals than at DDFs (Table 3).
Total 
N = 14885
Sentinel hospital (%) 
N1 = 12966
DDFs (%) 
N2 = 1919 χ2 (F) P
Age 38.5 ± 11.7 38.2 ± 11.7 41.0 ± 11.6 6.410 0.011
 18–44 11237 (75.5) 9826 (75.8) 1411 (73.6) 19.147 0.000
 45–60 2591 (17.4) 2266 (17.5) 325 (16.9)
 > 60 1056 (7.1) 874 (6.7) 182 (9.5)
Sex 2.008 0.156
 Man 10901 (73.2) 9522 (73.4) 1379 (71.9)
 Woman 3984 (26.8) 3445 (26.6) 539 (28.1)
Marital status
 Unmarried 4031 (27.1) 3662 (28.2) 369 (19.2) 128.183 0.000
 Divorce/widowed 1572 (10.6) 1258 (9.7) 314 (16.4)
 Married 9186 (61.7) 7972 (61.5) 1214 (63.3)
 Unknown 96 (0.6) 75 (0.6) 21 (1.1)
Transmission Route
 Blood 203 (1.4) 200 (1.5) 3 (0.2) 1693.445 0.000
 Injection drug users 2849 (19.1) 1855 (14.3) 994 (51.8)
 Men who have sex with men 2744 (18.4) 2727 (21.0) 17 (0.9)
 Heterosexual 8277 (55.6) 7468 (57.6) 809 (42.2)
 Mother to child 7 (0.0) 7 (0.1) 0 (0.0)
 Unknown 805 (5.4) 710 (5.5) 95 (5.0)
TB, PPT (+ ) 1127 (7.6) 1005 (7.8) 122 (6.4) 21.851 0.000
 Treat TB before ART 1048 (93.0) 947 (7.3) 101 (5.3)
 Un-treat TB before ART 79 (7.0) 58 (0.4) 21 (1.1)
Symptoms within 3 months
 No 9203 (61.8) 8107 (62.5) 1096 (57.1) 56.750 0.000
 Unknown 1330 (8.9) 1202 (9.3) 128 (6.7)
 Yes 4352 (29.2) 3658 (28.2) 694 (36.2) 141.160 0.000
 Fever > 37 °C> 1mon 2072 (13.9) 1831 (14.1) 241 (12.6)
 Diarrhea > 1mon 645 (4.3) 557 (4.3) 88 (4.6)
 Oral hairy leukoplakia 525 (3.5) 383 (3.0) 142 (7.4)
 Skin lesions 682 (4.6) 505 (3.9) 177 (9.2)
 Thrush 451 (3.0) 352 (2.7) 99 (5.2)
 Herpes zoster 907 (6.1) 783 (6.0) 124 (6.5)
Current symptoms
 Yes 5569 (37.4) 4541 (35.0) 1028 (53.6) 245.537 0.000
WHO Stage 12.167 0.000
 I–III 12094 (81.2) 10597 (81.7) 1497 (78.1)
 IV (AIDS) 2691 (18.1) 2291 (17.7) 400 (20.9)
Cotrimoxazole 3485 (23.4) 3190 (24.6) 295 (15.4) 79.423 0.000
 Previously used 11255 (75.6) 9698 (74.8) 1557 (81.2) 80.906 0.000
 Currently use 3249 (21.8) 2991 (23.1) 258 (13.5)
 Never used 236 (1.6) 201 (1.6) 35 (1.8)
CD4 cell count 27.078 0.000
 < 50 3535 (23.7) 3064 (23.6) 471 (24.6)
 50–199 5012 (33.7) 4281 (33.0) 731 (38.1)
 200–350 4861 (32.7) 4295 (33.1) 566 (29.5)
 > 350 777 (5.2) 702 (5.4) 75 (3.9)
 HBV (+ ) 1532 (10.3) 1319 (10.2) 213 (11.1) 1.555 0.212
 HCV (+ ) 1548 (10.4) 1034 (8.0) 514 (26.8) 634.720 0.000
Table 1.  Baseline Patient Characteristics.
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Linkage to care and retention rate in sentinel hospitals and DDFs. Among the 18,921 HIV patients 
seen in Guangdong Province, 16,074 (85.0%) were diagnosed in sentinel hospitals, 2,403 (12.7%) were diag-
nosed in DDFs, and 444 (2.3%) were diagnosed outside of Guangdong. As a result, linkage to care was 80.7% 
(12,966/16,074) in sentinel hospitals and 79.9% (1,919/2,403) in DDFs, respectively (P > 0.05).
Alive
P
Dead
P
Total alive (%) 
N = 14080
Sentinel hospital (%) 
N1 = 12431
DDFs (%) 
N2 = 1649
Total death (%) 
n = 805
Sentinel hospital (%) 
n1 = 536
DDFs (%) 
n2 = 269
Age 38.3 ± 11.7 38.0 ± 11.6 41.0 ± 11.7 0.198 42.0 ± 12.5 42.6 ± 13.2 40.9 ± 10.8 0.000
 18–44 10689 (75.9) 9482 (76.3) 1207 (73.2) 0.000 548 (68.1) 344 (64.2) 204 (75.8) 0.003
 45–60 2433 (17.3) 2150 (17.3) 283 (17.2) 158 (19.6) 116 (21.6) 42 (15.6)
 > 60 957 (6.8) 798 (6.4) 159 (9.6) 99 (12.3) 76 (14.2) 23 (8.6)
Sex 0.001 0.020
 Man 10226 (72.6) 9084 (73.1) 1142 (69.3) 675 (83.9) 438 (81.7) 237 (88.1)
 Woman 3854 (27.4) 3347 (26.9) 507 (30.7) 130 (16.1) 98 (18.3) 32 (11.9)
Marital status 0.000 0.179
 Unmarried 3861 (27.4) 3557 (28.6) 304 (18.4) 170 (21.1) 105 (19.6) 65 (24.2)
 Divorce/widowed 1463 (10.4) 1189 (9.6) 274 (16.6) 109 (13.5) 69 (12.9) 40 (14.9)
 Married 8673 (61.6) 7619 (61.3) 1054 (63.9) 513 (63.7) 353 (65.9) 160 (59.5)
 Unknown 83 (0.6) 66 (0.5) 17 (1.0) 13 (1.6) 9 (1.7) 4 (1.5)
Transmission Route 0.000 0.000
 Blood 190 (1.3) 188 (1.5) 2 (0.1) 13 (1.6) 12 (2.2) 1 (0.4)
 Injection drug users 2461 (17.5) 1660 (13.4) 801 (48.6) 388 (48.2) 195 (36.4) 193 (71.7)
 Men have sex with men 2733 (19.4) 2716 (21.8) 17 (1.0) 11 (1.4) 11 (2.1) 0 (0)
 Heterosexual 7934 (56.3) 7195 (57.9) 739 (44.8) 343 (42.6) 273 (50.9) 70 (26.0)
 Mother to child 7 (0.0) 7 (0.0) 0 (0) 0 (0) 0 (0) 0 (0)
 Unknown 755 (5.4) 665 (5.3) 90 (5.5) 50 (6.2) 45 (8.4) 5 (1.9)
TB, PPT (+ ) 1007 (7.2) 904 (7.3) 103 (6.3) 0.046 120 (14.9) 101 (19.2) 19 (7.3) 0.000
 Treat TB before ART 936 (92.9) 849 (93.9) 87 (84.5) 0.000 112 (93.3) 98 (97.0) 14 (73.7) 0.000
 Un-treat TB before ART 71 (7.1) 55 (6.1) 16 (15.5) 8 (6.7) 3 (3.0) 5 (26.3)
Symptoms within 3 months
 No 8950 (63.6) 7966 (64.1) 984 (59.7) 253 (31.4) 141 (26.3) 112 (41.6) 0.000
 Unknown 1204 (8.6) 1099 (8.8) 105 (6.4) 126 (15.7) 103 (19.2) 23 (8.6)
 Yes 3926 (27.9) 3366 (27.1) 560 (34.0) 0.000 426 (52.9) 292 (54.5) 134 (49.8)
 Fever > 37 °C > 1mon 1829 (13.0) 1648 (13.3) 181 (11.0) 0.000 243 (30.2) 183 (34.1) 60 (22.3)
 Diarrhea > 1mon 555 (3.9) 494 (4.0) 61 (3.7) 90 (11.2) 63 (11.8) 27 (10.0)
 Oral hairy leukoplakia 461 (3.3) 354 (2.8) 107 (6.5) 64 (8.0) 29 (5.4) 35 (13.0)
 Skin lesions 627 (4.5) 472 (3.8) 155 (9.4) 55 (6.8) 33 (6.2) 22 (8.2)
 Thrush 398 (2.8) 311 (2.5) 87 (5.3) 53 (6.6) 41 (7.6) 12 (4.5)
 Herpes zoster 808 (5.7) 723 (5.8) 85 (5.2) 99 (12.3) 60 (11.2) 39 (14.5) 0.000
Current symptoms
 Yes 5013 (35.6) 4177 (33.6) 836 (50.7) 0.000 556 (69.1) 364 (67.9) 192 (71.4) 0.000
WHO Stage
 I–III 11586 (82.3) 10251 (82.5) 1335 (81.0) 0.198 508 (63.1) 346 (64.6) 162 (60.2) 0.291
 IV (AIDS) 2410 (17.1) 2110 (17.0) 300 (18.2) 281 (34.9) 181 (33.8) 100 (37.2)
Cotrimoxazole 3273 (23.2) 3010 (24.2) 263 (15.9) 0.000 212 (26.3) 180 (33.6) 32 (11.9) 0.000
 Previously used 10678 (75.8) 9351 (75.2) 1327 (80.5) 0.000 577 (71.7) 347 (64.7) 230 (85.5) 0.000
 Currently use 3061 (21.7) 2832 (22.8) 229 (13.9) 0.000 188 (23.4) 159 (29.7) 29 (10.8) 0.000
 Never used 212 (1.5) 180 (1.4) 32 (1.9) 0.027 24 (3.0) 21 (3.9) 3 (1.1) 0.027
CD4 cell count
 < 50 3150 (22.4) 2794 (22.5) 356 (21.6) 0.006 385 (47.8) 270 (50.4) 115 (42.8) 0.000
 50–199 4736 (33.6) 4122 (33.2) 614 (37.2) 276 (34.3) 159 (29.7) 117 (43.5)
 200–350 4795 (34.1) 4257 (34.2) 538 (32.6) 66 (8.2) 38 (7.1) 28 (10.4)
 > 350 771 (5.5) 698 (5.6) 73 (4.4) 6 (0.7) 4 (0.7) 2 (0.7)
HBV (+ ) 1463 (10.4) 1275 (10.3) 188 (11.4) 0.002 69 (8.6) 44 (8.2) 25 (9.3) 0.845
HCV (+ ) 1436 (10.2) 986 (7.9) 450 (27.3) 0.000 112 (13.9) 48 (9.0) 64 (23.8) 0.000
Table 2.  Baseline Patient Characteristics Stratified by Mortality.
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Of those included in this analysis, 479 terminated treatments because of adverse effects to medication (11.5%), 
patient request (21.7%), poor adherence (61.6%), or other (5.3%). Retention rates were therefore 84.0% and 94.1% 
in DDFs and sentinel hospitals, respectively (P < 0.01). Crude HR of drug stopping in CDC health facilities was 
7.5 (95% CI: 6.3, 9.0) compared to sentinel hospitals (Table 4).
Long-term outcomes of sentinel hospitals and DDFs. The median follow up times in DDFs and sen-
tinel hospitals were 24.1 months (IQR, 7.1–31.2) and 28.1 months (IQR, 7.4–35.5), respectively. Of the 805 who 
died, 70.1% of those deaths were AIDS related, and 25.1% died from other complications. The overall excess mor-
tality rate was 0.8 deaths/100 person-years (95% CI: 0.6, 1.0). Excess mortality was 1.4 deaths/100 person-years 
(95% CI: 1.1, 1.8) in DDFs compared to 0.4 deaths/100 person-years (95% CI: 0.3, 0.5) in sentinel hospitals 
(Fig. 2) Kaplan-Meier analysis showed that the average survival time was 78.7 (95% CI, 76.2, 81.2) months in the 
DDFs group compared to sentinel hospitals at 105.3 (95% CI: 104.6, 106.1) months. As seen in Figure 3, mortality 
was much higher in patients receiving ART in the DDFs model (Fig. 3).
Risk factors related to death in Guangdong during long-term HAART. Gender, age at beginning 
HAART, baseline WHO stage and CD4 cell count, with complications of TB, HBV and Hepatitis C Virus (HCV) 
had unequally average unadjusted HR range from 1.3–9.6 times more risk of death. Those receiving treatment in 
a DDF after recruitment were 3.6 (95% CI: 3.1–4.2) times more at risk of death than those receiving treatment at 
a sentinel hospital (P < 0.01). Patients with a baseline CD4 cell count between 200–350 cells/ml had a higher risk 
of death compared to those with CD4 count > 350 cells/ml, however, this was not statistically significant.
In an adjusted Cox regression analysis, the strongest risk factors for death were having a nadir CD4 cell count 
less than 50 cells/ml and receiving ART in DDFs. Those with CD4 cell counts less than 50 cells/ml had an adjusted 
HR of 6.3 (95% CI, 2.2 to 20.0) compared to those with CD4 cell counts of 350 cells/ml or greater. Adjusted HR 
for those treated at a DDF was 3.3 (95% CI: 2.3, 4.6) compared to those treated in a sentinel hospital. Patients with 
HBV, HCV and TB baseline complications had adjusted HR of 1.7 (95% CI, 1.3, 2.4), 3.0 (95% CI, 2.8, 5.2) and 1.6 
(95% CI, 1.0, 2.0) respectively, compared to those without respective co-infections (Table 5).
Geographic distributions of HIV infections and treatment sites in Guangdong province. A gen-
eral overview of HIV reported from different cities in Guangdong illustrates HIV infection has a very specific 
geographic pattern. The highest rates of infection were seen in the Pearl River Delta and Yuexi regions with more 
than half of Guangdong’s HIV infections (51.0%) coming from the Pearl River Delta (Fig. 4a). Figure 4b illustrates 
the imbalance between geographic distributions of reported infections and health care facilities in Guangdong 
province. For example, the capital city of Guangzhou and the Special Economic Zone of Shenzhen accounted 
for 31.2% of all infections reported from 2005–2014 and are responsible for 32.1% of patients’ care in all health 
care facility, yet 46.6% (2,227/4,781) of patients were receiving ART management from outside of Guangzhou. In 
contrast to other cities, these health care facilities are usually responsible for 65.5%-100% of local patients’ care, 
respectively (Fig. 4b).
Total Baseline§
Total alive
Alive (IQR)
CDC-based DDFs Total death
Death (IQR) CDC-based 
DDFs
Last follow-up visit¶ (IQR)
(IQR) Sentinel hospital Sentinel hospital Total last visit Sentinel hospital CDC-based DDFs
CD4 (copies/μ l) 164 (51, 257) 170 (57, 261) 172 (57, 261) 160 (59, 258) 45 (15, 120)* 34 (13, 103) 66 (21, 150) 360 (239, 489)** 369 (250, 497) 264 (175, 392)
CD8 (copies/μ l) 746 (492, 1065) 753 (501, 1068) 745 (497, 1057) 809 (531,1173) 570 (321, 971)** 465 (269, 831) 738 (478, 1108) 828 (605,1123)* 827 (608, 1117) 845 (571, 1266)
Viral load (log) 5.1 (4.5, 5.6) 5.1 (4.5, 5.6) 5.2 (4.54, 5.65) 4.8 (4.2, 5.3) 5.2 (4.9, 5.5) 5.2 (4.6, 5.56) 5.2 (4.9, 5.2) 3442# (89.3) 3191 (92.4%) 251 (62.6%)
White blood cells (109/L) 4.8 (3.8, 6.1) 4.8 (3.8, 6.0) 4.8 (3.8, 6.0) 4.9 (3.9, 6.2) 4.5 (3.4, 6.5)* 4.4 (3.1, 6.3) 4.9 (3.8, 6.7) 5.7 (4.7, 6.9)* 5.6 (4.6, 6.8) 5.8 (4.7, 7.3)
Lymphocyte (109/L) 1.4 (1.0, 1.9) 1.4 (1.0, 2.0) 1.4 (1.0, 1.9) 1.5 (1.1, 2.1) 1.0 (0.6, 1.5)** 0.9 (0.5, 1.4) 1.2 (0.8, 1.6) 1.9 (1.5, 2.4)* 1.9 (1.5, 2.4) 1.9 (1.5, 2.5)
Plastocyte (109/L) 184 (146, 227) 184 (146, 227) 185 (147, 226) 181 (140, 233) 183 (127, 244) 182 (124, 247) 184 (134, 235) 213 (177, 253)* 214 (178, 253) 207 (162, 257)
Hemoglobin (g/L) 129 (112, 145) 130 (113, 146)* 131 (113, 146) 127 (113, 143) 109 (92, 126)* 106 (90, 125) 115 (99, 130) 140 (127, 152)* 141 (128, 152) 134 (120, 148)
Serum creatinine (μ mol/L) 72.9 (61.0, 85.0) 73.0 (61.0, 84.9) 72.9 (61.0, 84.4) 73.4 (62.0, 87.0) 71.2 (57.0, 86.8)* 71.2 (56.1, 85.3) 72.0 (59.0, 89.0) 76.0 (65.0, 88.2)* 76.0 (65.2, 88.0) 77.0 (64.0, 91.0)
Blood urea nitrogen 
(mmol/L) 4.1 (3.2, 5.0) 4.1 (3.2, 5.0) 4.1 (3.3, 5.0) 4.0 (3.2, 4.9) 3.9 (3.0, 5.2)* 3.9 (3.0, 5.3) 4.0 (3.0, 5.2) 4.4 (3.6, 5.3) 4.4 (3.7, 5.3) 4.4 (3.6, 5.4)
Triglyceride (mmol/L) 1.3 (1.0, 1.9) 1.3 (0.95, 1.86) 1.31 (0.96, 1.89) 1.25 (0.9, 1.7) 1.3 (1.0, 1.8) 1.4 (1.0, 1.9) 1.27 (0.93, 1.70) 1.6 (1.1, 2.5)* 1.6 (1.1, 2.6) 1.4 (1.0, 2.1)
Cholesterol (mmol/L) 4.0 (3.4, 4.7) 4.0 (3.4, 4.7) 4.0 (3.4, 4.7) 4.1 (3.4, 4.8) 3.5 (2.8, 4.2)** 3.5 (2.8, 4.3) 3.5 (2.9, 4.1) 4.6 (4.0, 5.3)* 4.6 (4.0, 5.3) 4.6 (4.0, 5.3)
Blood glucose (mmol/L) 5.2 (4.7, 5.7) 5.2 (4.7, 5.7) 5.1 (4.7, 5.6) 5.3 (4.8, 5.8) 5.2 (4.7, 5.8) 5.2 (4.7, 5.8) 5.1 (4.7, 5.6) 5.4 (5.0, 5.9)* 5.4 (5.0, 5.9) 5.5 (5.1, 5.9)
Hemodlastase (U/L) 69 (55, 89) 69 (55, 88) 68 (54, 86) 78 (60, 101) 72 (53, 99)** 70 (53, 100) 76 (56, 97.5) 69 (54, 88) 68 (53, 87) 83 (65, 102)
Glutamic-oxalacetic 
transaminase (U/L) 27 (21, 39) 27 (21, 38) 26 (20, 37) 32 (24, 46) 36 (26, 56)** 36 (25, 53) 38 (26, 62) 25 (20, 33)* 24 (19, 32) 33 (25, 49)
Glutamic-pyruvic 
transaminase (U/L) 24 (16, 40) 24 (16, 39) 24 (16, 39) 28 (18, 46) 28 (18, 45)** 28 (19,45) 27 (16, 47) 25 (17, 38) 24 (17, 37) 31 (22, 51)
Total bilirubin (μ mol/L) 9.7 (7.0, 13.2) 9.7 (7.0, 13.1) 9.7 (7.0, 13.1) 9.5 (6.7, 13.2) 9.3 (6.5, 13.8)* 8.8 (6.3, 13.1) 10.2 (6.9, 15.5) 8.7 (6.6, 11.4)** 8.8 (6.7, 11.5) 7.7 (5.7, 10.5)
Table 3.  Baseline Patient Characteristics Stratified by Mortality and Compared to Last Follow up Visit. 
Notice: 1. § Compare baseline between alive and death; ¶ compare to follow up and total baseline; 2. *P < 0.05, 
**P < 0.005. 3. #For the viral load at time of follow up, we reported changes to the proportion of those with 
undetectable VL (NA, < 40) to show the effectiveness of ART.
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Discussion
Our findings that patients receiving treatment from DDFs had an adjusted HR of mortality of 3.3 (95% CI: 2.3, 
4.6) as well as an unadjusted HR of stopping treatment of 7.5 (95% CI: 6.3, 9.0) compared to sentinel hospitals is 
cause for concern. The NFATP has significantly reduced the mortality rate among former blood and/or plasma 
donors partly because of their ease of management through the CDC-based DDFs or community hospitals in 
rural treatment settings despite having limited laboratory-monitoring24. Obviously, drugs stop is not only an 
indicator for ART evaluation but is also one of the barriers to achieving treatment-based prevention goals. The 
Guangdong province HIV/AIDS sentinel hospitals have modeled a system of integrated diagnosis, counseling 
and treatment instead of the national CDC leading health facilities, to help improve access and linkage to care, 
thereby increasing patient retention and adherence to ART regimens. However, investigations conducted in other 
provinces found that healthcare workers in general health facilities still face challenges other than providing pro-
fessional care for patients25,26.
This study directly compared two different HIV treatment models in Guangdong and revealed that the senti-
nel hospital model could improve patient outcomes and reduce treatment barriers. The observed mortality rate 
of 1.4 deaths/100 person-years in DDFs in Guangdong is similar to results from resource wealthy areas of the 
general population in nine industrialized countries (0.8–1.4 deaths/100 person-years)27. Additionally, the overall 
mortality rate in Guangdong, regardless of treatment sites, was 0.8 deaths/100 person-years, which is much lower 
than that observed in most Chinese national survey studies (4–6 deaths/100 person-years)28,29. We believe the 
early success of ART in sentinel hospitals of Guangdong province calls for optimism. This experience demon-
strates that it is possible, given proper resources and local government commitment, to treat many thousands 
of people in China’s urban settings. Studies have identified factors that reliably predict non-adherence to ART 
including demographic characteristics, illness experiences, social relations and so on. After adjusting for differ-
ences in patient characteristics, patients receiving care at funded facilities were more likely to achieve viral sup-
pression (1.1 [1.0–1.2])11. Proponents of a test-and-treat strategy for HIV prevention are aware of the importance 
Treatment sites$
Number of 
initiated ART 
(%) On-therapy (%)
Death Drug stop
Number of 
death (%)
Crude HR of 
Death (95% CI) P
Number of 
drug stop (%)
Crude HR of drug 
stop (95% CI) P
HIV/AIDS sentinel hospital 12966 (87.1) 12195 (89.7) 536 (4.1) 1.0 – 235 (1.8) 1.0 —
CDC-based DDFs 1919 (12.9) 1406 (10.3) 269 (14.0) 3.6 (3.1, 4.2) 0.000 244 (12.7) 7.5 (6.3, 9.0) 0.000
Table 4.  Long-Term Patient Outcomes Compared between Sentinel Hospitals and DDFs. $The median 
follow up times in DDFs and sentinel hospitals were 24.1 months (IQR, 7.1–31.2) and 28.1 months (IQR, 7.4–
35.5), respectively.
Figure 2. Overall excess mortality and survival rates between sentinel hospitals and CDC drug delivery 
health facilities. Overall change over time by mortality and life table survival rate. Mortality rate shown reflects 
each 3-month interval.
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and formidable challenges posed by poor engagement in HIV care. Nevertheless, levels of these indicators may 
differ among population groups with HIV/AIDS.
Our findings support results from most previous studies, showing that people with HIV who have hepatitis 
co-infection have an increasing risk of death after starting antiretroviral treatment in the first month30. With 
Figure 3. Kaplan–Meier analysis in sentinel hospital and drug deliver health facilities. Life table survival 
stratified by sentinel hospitals and CDC drug delivery health facilities after treatment initiation. Log-rank test, 
P < 0.001.
HR 95%CI P HRadj 95% CI P
Age
 18–44 1.0
 45–60 1.3 1.1–1.6 0.002 2.1 1.5–3.0
 > 60 2.3 1.9–2.9 0.000 2.5 1.3–4.1 0.001
Sex
 Female 1.0
 Male 2.2 1.8–2.7 0.000 1.4 1.0–2.0 0.010
HBV 1.0
2.0 1.5–2.7 0.000 1.7 1.3–2.4 0.001
HCV
3.7 2.9–4.8 0.000 3.0 2.2–4.3 0.000
TB 1.0
2.3 1.9–2.8 0.000 1.6 1.1–2.4 0.000
WHO
 I–III 1.0
 IV (AIDS) 2.3 2.0–2.7 0.000 1.6 1.1–2.1 0.005
CD4
 > 350 1.0
 200–350 1.6 0.7–3.7 0.265 1.3 0.4–4.4 0.480
 50–199 5.2 2.3–11.7 0.000 3.4 1.1–10.9 0.000
 < 50 9.6 4.3–21.6 0.000 6.3 2.0–20.0 0.000
Treatment sites
 Sentinel hospital 1.0
 CDC-based drug delivery health facility 3.6 3.1–4.2 0.000 3.3 2.3–4.6 0.000
Table 5.  Rates and Risk Factors for Death or Treatment Failure by Cox Proportional Hazards Regression.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:42637 | DOI: 10.1038/srep42637
the support of NFATP and other funding agencies, the Chinese government has demonstrated that the roll out 
of HIV care and treatment services in urban primary care sites is feasible on a large scale while maintaining 
favorable patient outcomes. Despite the burgeoning availability of ART, HIV prevention remains critical in urban 
China, where each year an estimated 100,000 adults and children become infected and the same amount increas-
ing to meet criteria for ART initiation. By the end of 2014, there were 3,952 antiretroviral treatment institutions 
in 2,312 counties/districts within 31 provinces, autonomous regions or municipalities around the country20. 
Therefore, besides Guangdong, there are nearly 1,000 hospitals and health facilities in each province in Guangxi, 
Henan and Yunan respectively. Here, policymakers and funders of health care need to develop more concrete 
steps to strengthen the management of delegating physician-level tasks to less qualified staff when planning for 
Figure 4. Geographic distribution of HIV infections in Guangdong Province of China from 2005–2014. 
(a) Geographic distribution of HIV prevelance in Guangdong. (b) Map representing patients seeking HIV 
treatment in other cities within Guangdong. Each city is represented by a unique color. Pie charts illustrate the 
percentages of patients receiving ART at each treatment facility with the color of the pie piece coorelating to 
the patients’ city if origin. All maps were generated using ArcGIS version 10.2 (http://www.esri.com/software/
arcgis/arcgis-for-desktop/free-trial).
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the amount and cost of the hospital-based treatment regimens required in the hospital from CDC. Looking at the 
change in CD4 cell count at ART initiation within each treatment site may be a better way to determine treatment 
success in getting patients treated earlier. But due to the observational nature of the database, it is unclear if the 
late ART initiation in our study was the result of late HIV diagnosis, delayed enrollment into HIV care, or late 
ART initiation despite timely enrolment in care. In conclusion, the median CD4 cell count at ART initiation was 
low in our cohort, however this did increase by the last follow up visit.
Low retention in CDC-based DDFs or community hospitals was likely in part the result of less qualified 
healthcare workers dispensing medications. The prevalence of HIV infection and number of patients seeking 
care varies greatly by region as seen in a recent study reporting variation by geographic location within Guangxi 
China31. More and more patients with advanced disease may have attended higher-level facilities, such as sentinel 
hospitals, for treatment and ART initiation, as they are generally perceived to offer better health services than 
community hospitals32. In light of the results mentioned above, a scale up of the sentinel hospital model could 
enhance linkage to supportive care, reduce treatment barrier, increase CD4 follow-up management, and expand 
CD4 baseline coverage, thereby improving overall patient outcomes. Additional research, however, is still needed 
to develop interventions aimed at increasing the balance of ART management in the different sentinel hospitals.
In this study, we compared the long-term outcomes of sentinel hospital-based and CDC-based ART delivery 
systems in the developed province in China. As far as we know, this is the first cohort in China to compare the 
two different types of facilities and show that treatment in sentinel hospitals has the potential to improve patient 
outcomes and reduce treatment barriers. Improving ART management continues to remain a major public health 
challenge in China. Our findings add to the understanding of comprehensive management and control of HIV in 
developing countries, after the start of HAART more than 20 years ago. One limitation of this study is the inability 
to delineate the independent contribution of, for example, poor retention in care, delayed initiation of antiretrovi-
ral therapy, and poor adherence to antiretroviral therapy, when the same individuals are prone to deficits in all of 
these areas. We have made best estimates from available data, but these are further limited by our cross-sectional 
representation of the longitudinal process of engagement in care. Additionally, this study is focused on the spec-
trum of engagement in HIV care in the Guangdong province as a resource-rich setting. Obstacles to diagnosis 
of HIV infection, linkage to and retention in HIV care, and receipt of and adherence to antiretroviral therapy in 
resource-limited settings such as African countries are of critical importance to the global HIV epidemic and 
deserve their own evaluation. Our results may not be directly generalizable across the country. These data are 
from a resource-rich province where patient acuity levels may not be representative of their respective national 
HIV programs. We have described our data as being different from the national averages, but recognize the 
immigration variations across the participating treatment sites. Overall, our study has highlighted important 
differences in patient outcomes between the two different HIV treatment model systems in Guangdong, China. 
We believe further efforts should be made to adopt a sentinel hospital-based system of integrated HIV care and 
treatment.
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